- Home
- INDO vs NERV Comparison
INDO vs NERV Comparison
Compare INDO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDO
- NERV
- Stock Information
- Founded
- INDO 2018
- NERV 2007
- Country
- INDO Indonesia
- NERV United States
- Employees
- INDO N/A
- NERV N/A
- Industry
- INDO Oil & Gas Production
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- INDO Energy
- NERV Health Care
- Exchange
- INDO Nasdaq
- NERV Nasdaq
- Market Cap
- INDO 23.4M
- NERV 18.3M
- IPO Year
- INDO 2019
- NERV 2014
- Fundamental
- Price
- INDO $3.92
- NERV $2.62
- Analyst Decision
- INDO
- NERV Hold
- Analyst Count
- INDO 0
- NERV 1
- Target Price
- INDO N/A
- NERV $5.00
- AVG Volume (30 Days)
- INDO 10.3M
- NERV 12.0K
- Earning Date
- INDO 10-25-2024
- NERV 11-05-2024
- Dividend Yield
- INDO N/A
- NERV N/A
- EPS Growth
- INDO N/A
- NERV N/A
- EPS
- INDO N/A
- NERV N/A
- Revenue
- INDO $3,525,454.00
- NERV N/A
- Revenue This Year
- INDO N/A
- NERV N/A
- Revenue Next Year
- INDO N/A
- NERV N/A
- P/E Ratio
- INDO N/A
- NERV N/A
- Revenue Growth
- INDO N/A
- NERV N/A
- 52 Week Low
- INDO $2.03
- NERV $2.26
- 52 Week High
- INDO $6.65
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- INDO 52.84
- NERV 44.93
- Support Level
- INDO $4.32
- NERV $2.56
- Resistance Level
- INDO $5.23
- NERV $2.72
- Average True Range (ATR)
- INDO 0.69
- NERV 0.11
- MACD
- INDO -0.02
- NERV 0.00
- Stochastic Oscillator
- INDO 44.63
- NERV 30.38
About INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.